Acacia Pharma - FDA approves BARHEMSYS for PONV
The US FDA has approved Acacia Pharma’s lead asset, BARHEMSYS (reformulated amisulpride), for the management of post-operative nausea and vomiting (PONV). Rescue treatment for PONV is an unmet need. Acacia plans to launch BARHEMSYS in H220 and management has been slowly building up its US commercial operations. It now has 30 personnel in the US spanning six regional teams. With short-term funding secured through the ByFavo in-licence deal with Cosmo Pharmaceuticals, Acacia plans to recruit further key personnel required to support the product’s launch in H220. Importantly, the FDA has granted BARHEMSYS a broad label in PONV. Combined with economic saving data, this should support broad hospital formulary access. Our increased valuation is €15.2/share.Acacia Pharma Group Plc. Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the prophylaxis and treatment of Postoperative nausea and vomiting (PONV), and APD403, which is based on the selective dopamine antagonist amisulpride and it is being developed as an intravenous injection for cancer patients to be administered immediately before chemotherapy to prevent acute chemotherapy-induced nausea & vomiting ( CINV).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.